Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Chronic Bowel Disorders: Introduction

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The mortality rate from self-harm in Iran.

Public health·2020

Same author

Trend of fatal poisoning at national and provincial levels in Iran from 1990 to 2015.

Public health·2019

Same author

Early Caries in an In Vivo Model: Structural and Nanomechanical Characterization.

Journal of dental research·2018

Same author

Neural stem/progenitor cell transplantation for spinal cord injury treatment; A systematic review and meta-analysis.

Neuroscience·2016

Same author

Potential variables affecting the quality of animal studies regarding pathophysiology of traumatic spinal cord injuries.

Spinal cord·2015

Same author

Synthesis of silver nanoparticles: chemical, physical and biological methods.

Research in pharmaceutical sciences·2015

Search research articles

Related Experiment Videos

Synbiotic preparation in men suffering from functional constipation: a randomised controlled trial.

R Fateh¹, S Iravani, M Frootan

¹School of Medicine, Tehran University of Medical Sciences, IR. rouzbehfateh@student.tums.ac.ir

Swiss Medical Weekly

|August 2, 2011

Summary

A synbiotic preparation significantly improved stool frequency and consistency in men with functional constipation over 4 weeks. No adverse effects were reported, suggesting potential benefits for this condition.

Related Experiment Videos

Area of Science:

Gastroenterology
Microbiome Research
Clinical Nutrition

Background:

Functional constipation affects a significant portion of the male population.
Synbiotics, combining prebiotics and probiotics, offer a potential therapeutic avenue.
Evaluating commercial synbiotic efficacy in male functional constipation is crucial.

Purpose of the Study:

To assess the impact of a commercial synbiotic preparation on functional constipation in adult males.
To determine changes in stool frequency and consistency.

Main Methods:

A randomized controlled trial involving 66 adult men with functional constipation.
Participants received either a synbiotic mixture or a placebo twice daily for 4 weeks.
Stool frequency and Bristol stool form score were primary outcome measures.

Main Results:

The synbiotic group showed a significant increase in stool frequency at weeks 2 and 4 compared to placebo (p=0.02).
Significant improvements in Bristol stool form score were observed in the synbiotic group at weeks 2 and 4 (p=0.006).
No adverse effects were reported in the synbiotic group.

Conclusions:

The studied synbiotic preparation demonstrated efficacy in improving stool frequency and consistency in males with functional constipation.
Further research with longer follow-up periods and diverse populations (females, elderly) is warranted.
This synbiotic may be a beneficial option for managing functional constipation in men.